Health
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
WILMINGTON, Del., February 03, 2026--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1181,"height":286,"url":"https://media.zenfs.com/en/business-wire.com/d711f3f61d9544e17bc96314bea849c1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BBWZq1Wkf.HwqWR9aK9NMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d711f3f61d9544e17bc96314bea849c1","width":960,"height":232},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/28CkNsGfWTsKTM83XVCtfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNjI7aD01NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d711f3f61d9544e17bc96314bea849c1","width":1181,"height":286}},"lazy":false},{"type":"text","content":"Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo’s DATROWAY significantly improved overall survival vs. chemotherapy in this patient population","length":173,"tagName":"p","attribs":{}},{"type":"text","content":"If approved, DATROWAY could become the standard of care in this setting","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., February 03, 2026--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.","length":398,"tagName":"p"},{"type":"text","content":"The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for its regulatory decision, is anticipated during the second quarter of 2026.","length":433,"tagName":"p"},{"type":"text","content":"The sBLA is being reviewed under Project Orbis, which provides a framework for concurrent submission and review of oncology medicines among participating international partners. This initiative is designed to bring effective cancer treatments to patients as early as possible.","length":276,"tagName":"...